Soft-Tissue and Osteosarcomas
If it’s your first time on this website, please read the disclaimer section.
Jun 29 – Jul 06, 2026
Outcome of metastatic non-rhabdomyosarcoma soft tissue sarcoma in children and young adults treated on children’s oncology group ARST0332 trial.
JNCI-J NATL CANCER I · Q1 JOURNAL - RANK #44/326
This prospective trial investigated clinical outcomes in 80 children and young adults with metastatic non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) treated on the Children’s Oncology Group ARST0332 trial with multimodal therapy including ifosfamide, doxorubicin, surgery, and radiotherapy. Event-free survival (EFS) and overall survival (OS) were calculated, with a 5-year EFS of 21% (95% CI, 11–31) and OS of 36% (95% CI, 24–47); the response rate at week 13 was 41%. Univariable analyses identified histologic subtype, number of metastatic sites, and early response as prognostic. The study concludes that prognosis remains poor and that future strategies should be informed by biology and early treatment response.
10.1093/jnci/djag211
Jun 22 – Jun 29, 2026
Any impact of pre-operative radiotherapy on renal function in retroperitoneal soft tissue sarcomas? A secondary ancillary analysis of the EORTC 62092 STRASS 1 trial.
RADIOTHER ONCOL · Q1 JOURNAL - RANK #22/212
Conducted as an ancillary analysis of the prospective, randomized EORTC 62092 STRASS 1 trial for retroperitoneal sarcoma, this study examined whether preoperative radiotherapy and subsequent surgery affected renal function compared with surgery alone. Researchers evaluated 181 of the 266 patients, comparing creatinine clearance (CrCl) and RIFLE events up to day 60 post-surgery. Primary findings showed no significant association between radiotherapy dose to the kidney and RIFLE risk, with 170 total RIFLE events (96.7% in the surgery alone arm vs 91.1% in the preoperative RT arm). At 80 months of follow-up, preoperative radiotherapy did not increase the risk of renal complications.
10.1016/j.radonc.2026.111672
Efficacy of hydrocolloid dressing for hand-foot skin reaction: J-SUPPORT 1701 APRON trial.
SUPPORT CARE CANCER · Q1 JOURNAL - RANK #17/173
This phase 3 randomized self-controlled study evaluated the efficacy of hydrocolloid dressing versus standard prophylactic moisturizing alone in preventing hand-foot skin reaction (HFSR) among 50 patients with unresectable colorectal cancer, gastrointestinal stromal tumors, or hepatocellular carcinoma receiving regorafenib or sorafenib. The primary endpoint was incidence of grade 2 or higher HFSR, assessed with blinded central review and patient-reported outcomes. Results showed a significantly lower rate of grade 2 or higher HFSR in the hydrocolloid group versus control (20% vs. 50%, p < 0.0001; HR for time to event 0.32, p = 0.0017) and reduced patient-reported moderate to severe HFSR (10% vs. 32%, p = 0.0002). The authors concluded that hydrocolloid dressings provide effective prophylaxis for HFSR in this population.
10.1007/s00520-026-10902-9
Jun 08 – Jun 15, 2026
Utidelone in patients with advanced soft tissue sarcoma refractory to anthracycline and antiangiogenic therapy (UTISARC): a single-arm phase II study.
BMC MED · Q1 JOURNAL - RANK #19/332
This single-arm phase II clinical trial investigated the efficacy and safety of utidelone, an epothilone analog, in 27 adults with advanced or metastatic soft tissue sarcoma refractory to both anthracycline-based chemotherapy and antiangiogenic tyrosine kinase inhibitors. Patients received utidelone intravenously at 30 mg/m² for five consecutive days every three weeks until disease progression or toxicity, with the primary endpoint of median progression-free survival. Results showed a median progression-free survival of 4.6 months (95% CI, 3.6-5.6), an objective response rate of 7%, and 80% estimated 12-month overall survival. The study concluded that utidelone exhibited preliminary antitumor activity and manageable safety, supporting further investigation.
10.1186/s12916-026-04990-x
Anlotinib plus toripalimab in patients with advanced bone and soft tissue sarcomas including ultra-rare sarcomas: A multicenter, single-arm, phase 2 trial.
EUR J CANCER · Q1 JOURNAL - RANK #45/326
This multicenter, single-arm, phase 2 clinical trial evaluated the effectiveness and safety of anlotinib plus toripalimab in 70 patients with advanced bone and soft tissue sarcomas, including 34 with ultra-rare sarcomas. Patients received set doses of both drugs every 3 weeks, with a median follow-up of 29.6 months. The confirmed objective response rate was 29% (95% CI: 19-42%), disease control rate was 90% (95% CI: 80-96%), median progression-free survival was 7.0 months, and median overall survival was 27.0 months; a post-hoc analysis linked lower baseline monocyte counts with better outcomes. The study concluded that the combination showed promising activity and manageable toxicity, especially in ultra-rare sarcomas.
10.1016/j.ejca.2026.116871
Jun 01 – Jun 08, 2026
Phase 1 trial of pre-operative image guided intensity modulated photon radiotherapy with simultaneously integrated boost to the high-risk margin for patients with retroperitoneal sarcoma.
RADIOTHER ONCOL · Q1 JOURNAL - RANK #22/212
This phase 1 trial assessed pre-operative intensity modulated photon radiotherapy with a simultaneously integrated boost to a high-risk tumor margin in patients with retroperitoneal sarcoma. Using a dose-escalation design, patients received up to 63 Gy to the high-risk margin. The trial found that the dose escalation was safe and demonstrated potential efficacy, warranting further prospective investigation. These findings suggest that intensifying radiation to high-risk margins may improve local control and patient outcomes.
10.1016/j.radonc.2026.111621
May 25 – Jun 01, 2026
Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.
NAT MED · Q1 JOURNAL - RANK #1/195TOP-TIER
This prospective, single-arm phase 2 trial evaluated the pan-FGFR inhibitor rogaratinib in advanced SDH-deficient gastrointestinal stromal tumors, with a primary objective of objective response rate and secondary endpoints of progression-free survival (PFS) and safety; exploratory serial biopsies assessed FGF3/FGF4, FGFRs, whole-exome sequencing, and PK/PD. Twenty-four patients were treated; 10 achieved partial responses for an ORR of 41.7%. Median PFS was 31.0 months (95% CI 20.2–not reached) and 1-year PFS was 77.4% (95% CI 61.7–97.1). Toxicities were manageable (hyperphosphatemia, fatigue, diarrhea), phosphorus elevations indicated FGFR1 target engagement, and sequencing confirmed SDHx alterations, supporting FGFR inhibition as an effective targeted therapy in this epigenetically driven GIST subtype (NCT04595747).
10.1038/s41591-026-04376-9